Paratek Pharmaceuticals, Inc. (PRTK): Price and Financial Metrics

Paratek Pharmaceuticals, Inc. (PRTK): $2.23

0.04 (+1.83%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

B

Add PRTK to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#48 of 382

in industry

PRTK Price/Volume Stats

Current price $2.23 52-week high $3.65
Prev. close $2.19 52-week low $1.29
Day low $2.19 Volume 4,764,400
Day high $2.24 Avg. volume 724,253
50-day MA $2.20 Dividend yield N/A
200-day MA $2.06 Market Cap 127.83M

PRTK Stock Price Chart Interactive Chart >


Paratek Pharmaceuticals, Inc. (PRTK) Company Bio


Paratek Pharmaceuticals focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. The company was founded in 1996 and is based in in Boston, Massachusetts.


PRTK Latest News Stream


Event/Time News Detail
Loading, please wait...

PRTK Latest Social Stream


Loading social stream, please wait...

View Full PRTK Social Stream

Latest PRTK News From Around the Web

Below are the latest news stories about PARATEK PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PRTK as an investment opportunity.

Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats. The Company's lead commercial product, NUZYRA® (omadacycline),

Yahoo | September 21, 2023

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the company

Key Insights Significantly high institutional ownership implies Paratek Pharmaceuticals' stock price is sensitive to...

Yahoo | September 19, 2023

Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek’s special meeting of stockholders, in connection with the previously announced definitive agreemen

Yahoo | September 18, 2023

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S

Follows the recommendation from ISS to vote FOR the transactionBOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that a second leading independent proxy advisor Glass, Lewis & Co. (“Glass Lewis”) has recommended that stockholders vote FOR the Company's prev

Yahoo | September 12, 2023

Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that leading independent proxy advisor Institutional Shareholder Services Inc. (“ISS”) has recommended that stockholders vote FOR the Company's previously announced definitive agreement to be acquired by Gur

Yahoo | September 7, 2023

Read More 'PRTK' Stories Here

PRTK Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 14.36%
3-year -68.01%
5-year -58.40%
YTD N/A
2023 0.00%
2022 -58.35%
2021 -28.27%
2020 55.33%
2019 -21.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!